Alkermes announces publication of 56-week post hoc analysis of Lybalvi

Alkermes (ALKS) announced the publication of a 56-week post hoc analysis of the effects of Lybalvi on negative symptoms in adults living with schizophrenia in the peer-reviewed publication The Journal of Clinical Psychiatry. The analysis-titled “The Efficacy of Olanzapine/Samidorphan on Negative Symptoms: A Post Hoc Analysis of 56-Week Treatment in Patients With Schizophrenia”-found that treatment with Lybalvi was associated with improvement in mean negative symptom scores. Lybalvi is approved in the U.S. for the treatment of schizophrenia in adults, and for the treatment of bipolar I disorder in adults, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or as adjunct to lithium or valproate.